Zhao Li-Na, Yu Tao, Lan Shao-Yang, Hou Jiang-Tao, Zhang Zheng-Zheng, Wang Shuang-Shuang, Liu Feng-Bin
Department of Gastroenterology, the First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China.
Department of Gastroenterology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Clin Res Hepatol Gastroenterol. 2015 Dec;39(6):674-82. doi: 10.1016/j.clinre.2015.03.008. Epub 2015 May 5.
Although the efficacy of probiotics has been extensively studied in hepatic encephalopathy (HE), the results remain controversial. The objective of this study is to identify and update the association between probiotics and HE.
Up to December 2014, we searched Medline, Embase, Web of Science, Cochrane CENTRAL, and SinoMed of China for all relevant articles about probiotics and HE. Jadad score was used to evaluate the quality of studies. Pooled relative risk (RR), publication bias and heterogeneity were assessed.
Nine studies met the inclusion criteria. Probiotics was associated with improvement of minimal HE and prophylaxis of overt HE [RR 1.52; 95% confidence intervals (95% CI) 1.00-2.33]. Studies with probiotics showed reduction of ammonia concentration [standard mean difference (SMD) -0.32, 95% CI -0.54 to -0.11]. Probiotics could reduce physical and psychosocial sickness impact profile (SIP) score with weight mean difference (WMD) -3.13 (95% CI -4.10 to -2.17) and WMD -3.50 (95% CI -4.91 to -2.08), respectively. Similar result was obtained with total SIP score (WMD -4.83; 95% CI -6.24 to -3.43). Reduction of severe adverse events, defined as minimal HE developing into overt HE, hospitalizations, infections or unrelated emergency room (ER) visits, was observed in HE with probiotics (RR 0.59; 95% CI 0.39-0.90).
Our pooled results indicated that probiotics was associated with improvement of minimal HE, prophylaxis of overt HE, and reduction of SIP score and severe adverse events. Large well-designed randomised controlled trials are needed to confirm these results.
尽管益生菌在肝性脑病(HE)中的疗效已得到广泛研究,但结果仍存在争议。本研究的目的是确定并更新益生菌与HE之间的关联。
截至2014年12月,我们检索了Medline、Embase、科学网、Cochrane中心对照试验注册库以及中国生物医学文献数据库,以查找所有关于益生菌与HE的相关文章。采用Jadad评分来评估研究质量。评估合并相对风险(RR)、发表偏倚和异质性。
九项研究符合纳入标准。益生菌与改善轻微型HE及预防显性HE相关[RR 1.52;95%置信区间(95%CI)1.00 - 2.33]。使用益生菌的研究显示氨浓度降低[标准均数差(SMD)-0.32,95%CI -0.54至-0.11]。益生菌可分别降低身体和心理社会疾病影响概况(SIP)评分,加权均数差(WMD)为-3.13(95%CI -4.10至-2.17)和WMD -3.50(95%CI -4.91至-2.08)。总SIP评分也得到类似结果(WMD -4.83;95%CI -6.24至-3.43)。在使用益生菌的HE患者中,观察到严重不良事件减少,严重不良事件定义为轻微型HE发展为显性HE、住院、感染或无关的急诊室就诊(RR 0.59;95%CI 0.39 - 0.90)。
我们的汇总结果表明,益生菌与改善轻微型HE、预防显性HE以及降低SIP评分和严重不良事件相关。需要大型精心设计的随机对照试验来证实这些结果。